Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2017 1
2018 1
2019 1
2021 1
2024 2
2025 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

8 results

Results by year

Filters applied: . Clear all
Page 1
Post-exposure prophylaxis regimen of rabies monoclonal antibody and vaccine in category 3 potential exposure patients: a phase 4, open-label, randomised, active-controlled trial.
Kulkarni PS, Potey AV, Kapse D, Bhamare C, Gawande A, Munshi R, Pawar S, Gogtay NJ, Agarwal A, Tambe M, Thakre S, Samuel CJ, Khan SMS, S RH, Rana D, Singh N, Kamath V, Bhalla HL, Poonawalla CS, Mani RS, Gunale B; RAB-04 study group. Kulkarni PS, et al. Lancet. 2025 Aug 9;406(10503):627-635. doi: 10.1016/S0140-6736(25)00735-4. Lancet. 2025. PMID: 40783290 Clinical Trial.
Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine versus a quadrivalent meningococcal conjugate vaccine in adults in India: an observer-blind, randomised, active-controlled, phase 2/3 study.
Kulkarni PS, Kawade A, Kohli S, Munshi R, Maliye C, Gogtay NJ, S RH, Singh K, Vengadakrishnan K, Panigrahi SK, Sahoo J, Bavdekar A, Garg BS, Raut A, Raj JP, Saxena U, Chaudhari VL, Patil R, Venkatarao E, Kumari N, Surendran J, Parulekar V, Gagnon L, Gensale T, Dharmadhikari A, Gairola S, Kale S, Pisal SS, Dhere RM, Mallya A, Poonawalla CS, Kapse D. Kulkarni PS, et al. Among authors: surendran j. Lancet Infect Dis. 2025 Apr;25(4):399-410. doi: 10.1016/S1473-3099(24)00576-0. Epub 2024 Nov 6. Lancet Infect Dis. 2025. PMID: 39521012 Clinical Trial.
Defining the volume of rabies immunoglobulins/ rabies monoclonal antibodies requirement for wound infiltration of category III animal exposures - an exploratory study.
Haradanhalli RS, Kumari N, Sudarshan MK, Narayana DHA, Prashanth RM, Surendran J. Haradanhalli RS, et al. Among authors: surendran j. Hum Vaccin Immunother. 2021 Dec 2;17(12):5355-5360. doi: 10.1080/21645515.2021.2013079. Epub 2022 Jan 21. Hum Vaccin Immunother. 2021. PMID: 35061550 Free PMC article.
The ACT-ONE trial, a multicentre, randomised, double-blind, placebo-controlled, dose-finding study of the anabolic/catabolic transforming agent, MT-102 in subjects with cachexia related to stage III and IV non-small cell lung cancer and colorectal cancer: study design.
Stewart Coats AJ, Srinivasan V, Surendran J, Chiramana H, Vangipuram SR, Bhatt NN, Jain M, Shah S, Ali IA, Fuang HG, Hassan MZ, Beadle J, Tilson J, Kirwan BA, Anker SD; on behalf of the ACT-ONE Trial Investigators. Stewart Coats AJ, et al. Among authors: surendran j. J Cachexia Sarcopenia Muscle. 2011 Dec;2(4):201-207. doi: 10.1007/s13539-011-0046-2. Epub 2011 Oct 16. J Cachexia Sarcopenia Muscle. 2011. PMID: 22207908 Free PMC article.